EMA Releases Pharmacogenomics Concept Paper - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMA Releases Pharmacogenomics Concept Paper


ePT--the Electronic Newsletter of Pharmaceutical Technology

The EMA has released a concept paper for a guideline on pharmacogenomic methodologies in the evaluation of authorized medicines to address the fact that genetic differences can cause variability in drug-therapy efficacy and safety. The limited scope of clinical trials means that rare but serious adverse drug reactions (ADRs) may not be discovered until after increased population exposure post authorization.

Included in the topics proposed for the guideline are the following:

  • Systematic consideration of pharmacogenomic effects and the implications of genomic biomarkers in terms of efficacy, effectiveness, and safety
  • Early consideration of when post authorization genomic data should be monitored and collected to confirm appropriate dose or comedication
  • Collection of genomic material during clinical trials and in the case of serious ADRs, lack of effectiveness or worsening of the condition
  • Methodologies for post authorization safety studies, and post authorization efficacy and effectiveness studies
  • Consideration of the level and type of evidence for identification of signals and how to report to the competent authorities
  • Risk-minimization measures (depending on the importance of possible clinical implications)
  • Labeling issues, including what pharmacogenomic information to include in the product information.

The EMA press release stated, “Identifying individuals at risk of side effects, unexpected complications or lack of efficacy may help the development of strategies to optimize the use of medicines.” The concept paper is open for public consultation until Mar. 15, 2012.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here